Non-invasive vagus nerve stimulation is beneficial in chronic paroxysmal hemicrania by Kamourieh, S et al.
1J Neurol Neurosurg Psychiatry Month 2019 Vol 0 No 0
Letter
Non-invasive vagus nerve 
stimulation is beneficial in 
chronic paroxysmal hemicrania
IntroductIon
Paroxysmal hemicrania (PH) is a rare 
primary headache disorder charac-
terised by recurrent attacks of severe, 
strictly unilateral pain, focused around 
the orbital, supraorbital and temporal 
regions and associated with autonomic 
features. Attacks usually occur more 
than five times a day and last 2–30 min.1 
The disorder has an absolute response 
to indomethacin such that patients are 
rendered pain-free by therapeutic doses. 
Between 65% and 88% of patients suffer 
from the chronic form of PH where 
the attacks occur for more than 1 year 
without remission or with remission 
periods lasting less than 3 months.2 
Over 30% of patients report dose-lim-
iting side-effects with indomethacin and 
approximately 20% discontinue the drug 
due to tolerability problems.3 Although 
several other drugs have been reported 
to have efficacy in PH, none offer the 
same magnitude of response.
Evidence to support the role of the 
vagus nerve in trigeminal pain have 
been identified in prior studies. Inhi-
bition of nociceptive activation of the 
trigeminocervical neurons have been 
shown in preclinical animal models, 
with a dose-dependent effect.4 Non-in-
vasive vagus nerve stimulation (nVNS), 
using the gammaCore device, has been 
reported to be beneficial in trigeminal 
autonomic cephalalgias (TACs). A recent 
audit looking at 15 patients with indo-
methacin-responsive headaches, six of 
whom had PH, concluded that nVNS 
may be an important adjunct or alterna-
tive in those patients with TACs.5
Method
Given these results, we tried nVNS in 
eight chronic paroxysmal hemicrania 
(CPH) patients who were intolerant of 
indomethacin. Patients were diagnosed 
as CPH based on ICHD-3 beta criteria.1 
At initial presentation, some patients 
reported attacks lasting more than 30 
min though most of the attacks lasted 
less than 30 min; occasional prolonged 
attacks are a common feature in PH.2 
Prior to use, all patients had complete 
suppression of headaches with indo-
methacin but experienced significant side 
effects. One patient was on a stable dose 
of pregabalin prior to starting nVNS, 
the remainder were not on concomitant 
medication use. Treatment with nVNS 
was offered as a ‘humanitarian interven-
tion’ and ethics board approval for the 
collection and publication of data was 
granted by Northwick Park Hospital 
Research Ethics Committee, Hamp-
stead, London, UK (REC Number. 11/
LO/1709).
Patients administered two consecutive 
doses three times a day ipsilateral to the 
pain. The stimulator has a predetermined 
duration of 2 min and patients can change 
the stimulation intensity. The patients 
in this group were asked to increase the 
stimulation until the point of ‘lip pull’ to 
ensure optimal stimulation. They were 
trained on how to use the device and 
their technique was checked 4 weeks 
later to ensure it was optimal. Prospec-
tive headache diaries were kept at base-
line and throughout follow-up. Patients 
were followed up every 3–6 months when 
data were collected on headache disability 
scores (Migraine Disability Assessment 
Score (MIDAS) and Headache Impact Test 
(HIT-6) and affective measures (Hospital 
Anxiety and Depression Scale (HADS)).
ElectroCore supplied the devices 
through a cost sharing programme; the 
device was supplied free of charge for 3 
months and thereafter the device was paid 
for either by the patient or the healthcare 
provider.
results
The results of this case series are shown 
in table 1. The group consisted of eight 
patients (five males) with a mean age of 
48 years (range: 20–81 years) and median 
duration of CPH of 8 years (range 3–22 
years). Patients had failed to respond 
to an average of three preventive medi-
cations (range: 1–5) and all had dose 
limiting side effects to indomethacin. 
Median follow-up of the cohort was 7 
months (3–19 months). At 3 months, the 
mean monthly headache frequency fell by 
68.01% (p=0.012) but further dropped 
to 75% (p=0.003) at the final follow-up. 
A favourable response, defined as a more 
than 50% reduction in monthly head-
ache frequency, was observed in 75% of 
patients at final follow-up. The median 
time to reach a 50% improvement was 3 
months (range: 3–6 months). There was 
a reduction in median severity of attacks 
from verbal rating score (VRS) 8/10 to 
6/10 (p=0.050) at 3 months follow-up. 
At final follow-up, the median severity of 
attacks dropped from VRS 8/10 to 4/10 
(p=0.011). Similarly, there was a reduc-
tion in the median duration of attacks 
from 47.5 min to 21.25 min at 3 months 
follow-up (p=0.007) and at final follow-up 
to 23.1 min (p=0.007). Significant reduc-
tions were reported in HIT-6 and MIDAS 
scores. Seven patients showed a reduction 
in the Hospital Anxiety (HAD-A) scores, 
while four patients showed a reduction in 
the Hospital Depression (HAD-D) scores. 
The average estimated global improve-
ment was 64.37% and 71.88% at 3 
months and final follow-up, respectively. 
No adverse events were reported by any 
patients.
dIscussIon
Our experience suggests that nVNS has 
potential use as a preventative therapy for 
PH in patients unable to tolerate indo-
methacin. As detailed above, six of the 
eight patients had more than 50% reduc-
tion in frequency in their monthly head-
aches with significant improvements in 
their disability scores. We identified a 75% 
favourable response with two patients 
becoming attack-free.
There are limitations to these data, 
including those inherent to any unblinded 
series, though despite this our results are 
encouraging. The strength of the current 
series includes the use of prospective data. 
Further research into the use and safety 
of nVNS in PH is required. However, 
given the rarity of PH, it is unlikely that 
an adequately powered, randomised 
controlled trial will occur in the near 
future. Our results nonetheless highlight 
the potential importance of nVNS in this 
patient group and also the need to ensure 
patients adhere to treatment for at least 3 
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table 1 Non-invasive vagal nerve stimulation in chronic paroxysmal hemicrania
Patient number 1 2 3 4 5 6 7 8
Age 52 52 28 20 43 44 81 63
Sex Male Male Male Female Female Male Male Female
Duration of CPH 
(years) 3 11 3 6 22 11 8 5
Headache characteristics at diagnosis
Frequency 8–12/day 6–8/day 5–9/day 4–13/day 10–20/day 5–20/day 4–12/day 5–12/day
Severity (VRS) 10 5–10 7–10 8–10 6–10 4–8 10 8–10
Duration (min) 15–30 15–45 15–60 15–120 5–90 5–120 5–20 5–45
Median duration 
(min) 20 20 25 20 10 30 15 15
Indometacin dose 225 mg 100 mg 225 mg 75 mg 225 mg 225 mg 100 mg 225 mg
Side effects from 

















treatments failed 3 4 3 3 4 5 3 1
Duration of use of 
VNS (months) 19 10 6 6 7 5 7 3
Baseline headaches (1 month pre-VNS)
Frequency 5–10/day 2–3/day 5/day 1–2/day 5/day 2/day 4–5/day 2–5/day
Severity (VRS) 10 2–6 7–8 8–10 4–8 5–9 10 9–10
Duration (min) 20–30 30–90 45–60 15–120 5–80 60–120 15–20 30–45
Follow-up at 3 months
Frequency 2–3 week 1/day 2/week 5/month 1/day 1–2/day 0 2–5/day
Severity (VRS) 5–6 2–3 4–5 5–9 1–2 1–2 0 9–10
Duration (min) 15–20 30–60 20–30 5–20 5–30 30–60 0 30–45
Follow-up at 6 months
Frequency 1/week 1/day 2/week 5/month 0 N/A 0 N/A
Severity (VRS) 6–7 2–4 4–5 5–9 0 N/A 0 N/A
Duration (min) 15–20 30–60 20–30 5–20 0 N/A 0 N/A
Last follow-up
Frequency 1/week 1/day 2/week 5/month 0 1-2/day 0 2–5/day
Severity (VRS) 6–7 2–4 4–5 5–9 0 1–2 0 9–10
Duration (min) 20 30–60 20–30 5–20 0 30–60 0 30–45
HIT-6
Baseline 70 59 69 74 50 48 40 74
3 months 60 55 59 31 46 48 36 76
6 months 65 54 59 30 36 N/A 36 N/A
Last follow-up 66 54 59 30 36 48 36 N/A
MIDAS
Baseline 21 5 190 71 81 0 0 105
3 months 4 5 167 68 0 0 0 120
6 months 18 5 78 67 0 N/A 0 N/A
Last follow-up 14 5 78 67 0 0 0 N/A
HADS-A
Baseline 2 9 12 17 20 2 1 18
3 months 6 6 4 18 19 0 0 17
6 months 5 6 0 19 19 N/A 0 N/A
Last follow-up 3 6 0 19 19 0 0 N/A
HADS-D 
Baseline 3 6 14 14 16 2 1 15
3 months 1 5 7 14 9 0 0 16
6 months 3 5 0 15 9 N/A 0 N/A
Last follow-up 6 5 15 15 9 0 0 N/A
Patients estimate 
of improvement 70% 70% 90% 80% 100% 65% 100% 0%
CPH, chronic paroxysmal hemicrania; HADS-A/D, Hospital Anxiety and Depression Scale—Anxiety/Depression; HIT-6, Headache Impact Test-6; MIDAS, Migraine Disability 
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